(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.23%) $79.13
(-0.93%) $2.02
(0.01%) $2 309.80
(0.21%) $26.89
(0.36%) $966.10
(-0.06%) $0.932
(-0.10%) $10.98
(-0.14%) $0.797
(1.51%) $92.51
Live Chart Being Loaded With Signals
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo...
Stats | |
---|---|
Šios dienos apimtis | 135 629 |
Vidutinė apimtis | 214 032 |
Rinkos kapitalizacija | 857.14M |
EPS | $0 ( 2024-02-15 ) |
Kita pelno data | ( $-0.110 ) 2024-05-14 |
Last Dividend | $0.0300 ( 2015-12-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | -27.40 |
ATR14 | $0.0290 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Stanton Marshall S. | Sell | 2 183 | Common Stock |
2024-03-15 | Green Andrew M | Sell | 1 462 | Common Stock |
2024-03-14 | Green Andrew M | Sell | 3 994 | Common Stock |
2024-03-12 | Getz Matthew A | Sell | 5 000 | Common Stock |
2024-02-23 | Horton Amy | Buy | 6 418 | Common Stock |
INSIDER POWER |
---|
41.05 |
Last 100 transactions |
Buy: 409 992 | Sell: 170 182 |
Tūris Koreliacija
Artivion, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
BRF | 0.858 |
DEX | 0.846 |
GREK | 0.842 |
NTZ | 0.837 |
UBER | 0.836 |
RCL | 0.835 |
NTCO | 0.835 |
TWN | 0.829 |
IXSE | 0.828 |
QPX | 0.828 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
CGC | -0.844 |
RENN | -0.837 |
RLX | -0.831 |
QID | -0.825 |
PSQ | -0.823 |
LGF-A | -0.821 |
LGF-B | -0.821 |
SSG | -0.819 |
IDT | -0.819 |
BZQ | -0.818 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Artivion, Inc. Koreliacija - Valiuta/Žaliavos
Artivion, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $354.00M |
Bruto pelnas: | $213.98M (60.45 %) |
EPS: | $-0.750 |
FY | 2023 |
Pajamos: | $354.00M |
Bruto pelnas: | $213.98M (60.45 %) |
EPS: | $-0.750 |
FY | 2022 |
Pajamos: | $313.79M |
Bruto pelnas: | $202.52M (64.54 %) |
EPS: | $-0.480 |
FY | 2021 |
Pajamos: | $298.84M |
Bruto pelnas: | $197.51M (66.09 %) |
EPS: | $-0.392 |
Financial Reports:
No articles found.
Artivion, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0250 | 2012-09-12 |
Last Dividend | $0.0300 | 2015-12-09 |
Next Dividend | $0 | N/A |
Payout Date | 2015-12-18 | |
Next Payout Date | N/A | |
# dividends | 14 | -- |
Total Paid Out | $0.395 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.29 | -- |
Div. Sustainability Score | 3.78 | |
Div.Growth Potential Score | 0.523 | |
Div. Directional Score | 2.15 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0.0500 | 1.04% |
2013 | $0.108 | 1.61% |
2014 | $0.118 | 1.06% |
2015 | $0.120 | 1.07% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
ZTR | Dividend Royal | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0867 | 1.500 | -1.734 | -2.60 | [0 - 0.5] |
returnOnAssetsTTM | -0.0387 | 1.200 | -1.291 | -1.549 | [0 - 0.3] |
returnOnEquityTTM | -0.110 | 1.500 | -2.33 | -3.50 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.99 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.30 | 0.800 | 1.177 | 0.942 | [0.8 - 2.5] |
cashRatioTTM | 1.019 | 1.500 | 5.45 | 8.18 | [0.2 - 2] |
debtRatioTTM | 0.394 | -1.500 | 3.44 | -5.16 | [0 - 0.6] |
interestCoverageTTM | 0.268 | 1.000 | -1.012 | -1.012 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.454 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.273 | 2.00 | 9.86 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.107 | -1.500 | 5.57 | -8.36 | [0 - 2.5] |
grossProfitMarginTTM | 0.647 | 1.000 | 2.54 | 2.54 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0192 | 1.000 | -1.617 | -1.617 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0595 | 1.000 | -0.780 | -0.780 | [0.2 - 2] |
assetTurnoverTTM | 0.447 | 0.800 | -0.355 | -0.284 | [0.5 - 2] |
Total Score | 3.78 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -27.09 | 1.000 | -2.84 | 0 | [1 - 100] |
returnOnEquityTTM | -0.110 | 2.50 | -1.500 | -3.50 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.273 | 2.00 | 9.91 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.454 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.200 | 1.500 | -4.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0525 | 1.000 | -1.188 | 0 | [0.1 - 0.5] |
Total Score | 0.523 |
Artivion, Inc.
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.